Latest Treatment of schizophrenia Stories
TITUSVILLE, N.J., May 21 /PRNewswire/ -- New data on INVEGAÂ® SUSTENNAÂ® (paliperidone palmitate), a long-acting injectable medicine for schizophrenia, and new data on RISPERDALÂ® CONSTAÂ® (risperidone long-acting therapy), also an injectable medicine to treat schizophrenia, will be presented next week at a major psychiatry meeting in New Orleans.
WALTHAM, Mass., April 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Janssen's Invega Sustenna earns Decision Resources' proprietary clinical gold standard status for the treatment of schizophrenia in 2013.
The underlying causes of the debilitating psychiatric disorder schizophrenia remain poorly understood.
WALTHAM, Mass., Feb.
Schizophrenia is a Chronic, Severe and Disabling Mental Disorder Affecting 2.4 million Americans Novartis announced that Fanapt(TM) (iloperidone), the company's schizophrenia treatment, is now available for use across the US.
WATERTOWN, Mass., Jan. 5 /PRNewswire/ -- EnVivo Pharmaceuticals today announced the initiation and dosing of patients in a Phase 2b study of its EVP-6124 compound, a selective alpha-7 nicotinic agonist in patients with schizophrenia.
FORT LEE, N.J., Jan. 4 /PRNewswire/ -- Dainippon Sumitomo Pharma America, Inc. (DSPA), a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd. (DSP), submitted a New Drug Application (NDA) to the U.S.
INDIANAPOLIS, Dec. 14 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration (FDA) approved ZYPREXA RELPREVV (olanzapine) For Extended Release Injectable Suspension for the treatment of schizophrenia in adults, Eli Lilly and Company (NYSE: LLY) announced today.
TITUSVILLE, N.J., Dec. 10 /PRNewswire/ -- Treatment with once-monthly INVEGAÂ® SUSTENNA(TM) is not inferior to treatment with bi-weekly RISPERDALÂ® CONSTAÂ®, according to new data from a comparative study of both treatments in patients with schizophrenia.
INDIANAPOLIS, Dec. 4 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration (FDA) today approved ZyprexaÂ® (olanzapine) in tablet form as an option for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder in adolescents aged 13-17 years old.
- The act of sweetening by admixture of some saccharine substance.